![RAL - Ralliant Corp - Stock Price Chart]() |
Market Cap | 5.12B | EPS (ttm) | - |
P/E | - | EPS this Y | - |
Forward P/E | - | EPS next Y | - |
PEG | - | EPS past 5Y | - |
P/S | - | EPS next 5Y | - |
P/B | - | EPS Q/Q | - |
Dividend | - | Sales Q/Q | - |
Insider Own | - | Inst Own | - |
Insider Trans | - | Inst Trans | - |
Short Float | - | Earnings | - |
Analyst Recom | - | Target Price | - |
Avg Volume | 6.36M | 52W Range | 45.25 - 54.60 |
|
|
Jul-03-25 | Initiated |
BofA Securities |
Underperform |
$48 |
|
|
|
|
 |
![PMN - ProMIS Neurosciences Inc - Stock Price Chart]() |
Market Cap | 14.13M | EPS (ttm) | -0.04 |
P/E | - | EPS this Y | -684.85% |
Forward P/E | - | EPS next Y | 14.51% |
PEG | - | EPS past 5Y | - |
P/S | - | EPS next 5Y | - |
P/B | 1.49 | EPS Q/Q | -13.27% |
Dividend | - | Sales Q/Q | - |
Insider Own | 29.56% | Inst Own | 24.09% |
Insider Trans | 0.16% | Inst Trans | -12.90% |
Short Float | 0.61% | Earnings | May 12/b |
Analyst Recom | 1.00 | Target Price | 5.67 |
Avg Volume | 46.23K | 52W Range | 0.45 - 2.37 |
|
|
|
ProMIS Neurosciences, Inc. engages in the discovery and development of precision medicine solutions for early detection and effective treatment of neurodegenerative diseases. It focuses on the progression of Alzheimer's disease, amyotrophic lateral sclerosis, and Parkinson's disease. The company was founded by Neil Cashman and Vigen Nazarian on January 23, 2004 and is headquartered in Toronto, Canada. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Cashman Neil | Chief Scientific Officer | Feb 10 '25 | Buy | 0.97 | 15,000 | 14,595 | 16,617 | Feb 12 05:21 PM | Shafmaster Madge K. | Director | Sep 24 '24 | Buy | 1.30 | 70,000 | 91,028 | 208,333 | Sep 24 06:56 PM | Shafmaster Madge K. | Director | Sep 23 '24 | Buy | 1.28 | 70,000 | 89,656 | 138,333 | Sep 24 06:56 PM | Shafmaster Madge K. | Director | Sep 20 '24 | Buy | 1.25 | 60,000 | 75,066 | 68,333 | Sep 24 06:56 PM | GORDON MICHAEL S | 10% Owner | Sep 16 '24 | Buy | 1.22 | 76,931 | 94,071 | 76,931 | Sep 18 04:15 PM |
|
|
 |
![TELO - Telomir Pharmaceuticals Inc - Stock Price Chart]() |
Market Cap | 34.23M | EPS (ttm) | -0.42 |
P/E | - | EPS this Y | 44.64% |
Forward P/E | - | EPS next Y | 9.68% |
PEG | - | EPS past 5Y | - |
P/S | - | EPS next 5Y | - |
P/B | - | EPS Q/Q | 67.50% |
Dividend | - | Sales Q/Q | - |
Insider Own | 42.03% | Inst Own | 12.39% |
Insider Trans | 0.00% | Inst Trans | 3.31% |
Short Float | 12.12% | Earnings | May 28 |
Analyst Recom | 1.00 | Target Price | 15.50 |
Avg Volume | 252.85K | 52W Range | 1.18 - 8.40 |
|
|
|
Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company, which focuses on the development and commercialization of TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic treatment for human stem cells. The firm's initial focus on treatments to inhibit the production of pro-inflammatory cytokines, such as IL-17, by oral administration of TELOMIR-1 as a therapeutic treatment for stem cells in situ. TELOMIR-1 is under investigation to provide a potential therapeutic intervention against age-related inflammatory conditions such as hemochromatosis, as well as for post-chemotherapy recovery, by interrupting and preventing the IL-17 induced inflammatory pathways that create the systemic imbalance of cellular metals. The company was founded by Christopher C. Chapman Jr. on August 26, 2021 and is headquartered in Miami, FL. |
|
|  |
![NEHC - New Era Helium Inc - Stock Price Chart]() |
Market Cap | 6.19M | EPS (ttm) | -1.30 |
P/E | - | EPS this Y | - |
Forward P/E | - | EPS next Y | - |
PEG | - | EPS past 5Y | -914.89% |
P/S | 12.14 | EPS next 5Y | - |
P/B | - | EPS Q/Q | -873.58% |
Dividend | - | Sales Q/Q | - |
Insider Own | 57.07% | Inst Own | 2.14% |
Insider Trans | 0.00% | Inst Trans | 23.63% |
Short Float | 37.17% | Earnings | - |
Analyst Recom | - | Target Price | - |
Avg Volume | 5.33M | 52W Range | 0.43 - 12.29 |
|
|
|
New Era Helium, Inc. is an exploration and production company, which engages in selling oil and natural gas products. The company was founded on February 6, 2023 and is headquartered in Midland, TX. |
|
 |
![JXG - JX Luxventure Group Inc - Stock Price Chart]() |
Market Cap | 6.55M | EPS (ttm) | 2.14 |
P/E | 0.76 | EPS this Y | - |
Forward P/E | - | EPS next Y | - |
PEG | - | EPS past 5Y | - |
P/S | 0.13 | EPS next 5Y | - |
P/B | 0.07 | EPS Q/Q | -57.68% |
Dividend | - | Sales Q/Q | -36.53% |
Insider Own | 6.04% | Inst Own | 0.14% |
Insider Trans | 0.00% | Inst Trans | -83.53% |
Short Float | 0.34% | Earnings | - |
Analyst Recom | - | Target Price | - |
Avg Volume | 133.50K | 52W Range | 1.41 - 8.40 |
|
|
|
JX Luxventure Group, Inc. engages in the design, manufacture, distribution, and sale of casual menswear. It operates through the following segments: Tourism Products, Technology, and Cross-Board Merchandise. The The company was founded by Anna Polemis on January 26, 2012, and is headquartered in Haikou, China. |
|
|  |
![FOXO - FOXO Technologies Inc - Stock Price Chart]() |
Market Cap | 3.53M | EPS (ttm) | -7.93 |
P/E | - | EPS this Y | - |
Forward P/E | - | EPS next Y | - |
PEG | - | EPS past 5Y | -7.61% |
P/S | 0.49 | EPS next 5Y | - |
P/B | 0.06 | EPS Q/Q | 84.81% |
Dividend | - | Sales Q/Q | 39918.93% |
Insider Own | 2.27% | Inst Own | 0.24% |
Insider Trans | 0.00% | Inst Trans | 0.27% |
Short Float | 1.98% | Earnings | - |
Analyst Recom | - | Target Price | - |
Avg Volume | 6.25M | 52W Range | 0.17 - 13.00 |
|
|
|
FOXO Technologies, Inc. develops genetic sequencing technology, artificial intelligence and bioinformatics tools. It operates through the FOXO Labs and FOXO Life segments. The FOXO Labs segment is involved in research and development and is commercializing proprietary epigenetic biomarker technology. The FOXO Life segment is involved in combining life insurance with a dynamic molecular health and wellness platform. The company was founded on April 27, 2020 and is headquartered in West Palm Beach, FL. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Kr8 ai Inc. | 10% Owner | Jul 22 '24 | Sale | 0.25 | 1,300,000 | 325,000 | 0 | Jul 24 04:00 PM | WHITE MARK BRIAN | Interim CEO | Jul 22 '24 | Sale | 0.25 | 1,300,000 | 325,000 | 0 | Jul 24 04:00 PM | WARD MARTIN CHRISTOPHER | Interim CFO | Jul 22 '24 | Sale | 0.25 | 1,300,000 | 325,000 | 0 | Jul 24 04:00 PM |
|
|
 |
![CNC - Centene Corp - Stock Price Chart]() |
Market Cap | 16.58B | EPS (ttm) | 6.72 |
P/E | 4.96 | EPS this Y | 1.95% |
Forward P/E | 4.17 | EPS next Y | 9.38% |
PEG | 0.57 | EPS past 5Y | 14.96% |
P/S | 0.10 | EPS next 5Y | 8.64% |
P/B | 0.59 | EPS Q/Q | 21.75% |
Dividend | 3.00% | Sales Q/Q | 15.38% |
Insider Own | 1.17% | Inst Own | 98.49% |
Insider Trans | 0.00% | Inst Trans | 0.93% |
Short Float | 1.89% | Earnings | Jul 25/b |
Analyst Recom | 2.23 | Target Price | 65.88 |
Avg Volume | 6.65M | 52W Range | 33.76 - 80.59 |
|
|
Jul-02-25 | Downgrade |
UBS |
Buy → Neutral |
$45 |
Jul-02-25 | Downgrade |
JP Morgan |
Overweight → Neutral |
$48 |
|
Jul-05-25 10:43AM
|
Jim Cramer on Centene: "Very Painful Story"
(Insider Monkey) |
Jul-04-25 09:59AM
|
UnitedHealth Under Fire as Medicaid & Centene Bombshell Rattle Sector
(Zacks) |
Jul-03-25 04:47PM
|
Analyst Report: Centene Corporation
(Morningstar Research) |
09:50AM
|
These Stocks Are Moving the Most Today: Tesla, Lucid, Datadog, Synopsys, Tripadvisor, Olo, Centene, and More
(Barrons.com) |
08:32AM
|
Zacks.com featured highlights include Hudbay Minerals, StoneCo, Centene and CVS Health
(Zacks) |
05:22AM
|
These Stocks Are Moving the Most Today: Tesla, Lucid, Datadog, Centene, Tripadvisor, and More
(Barrons.com) |
04:52AM
|
Company News for Jul 3, 2025
(Zacks) |
02:47AM
|
BofA Securities Reduces PT on Centene Corporation (CNC) Stock
(Insider Monkey) |
Jul-02-25 10:12PM
|
Centene Stock Plunges 40% to an 8-Year LowWatch These Key Price Levels
(Investopedia) -40.37% |
08:28PM
|
Jim Cramer on what is behind Centene's 40% drop
(CNBC TV) |
|
Centene Corp. is a healthcare enterprise, which engages in the provision of programs and services to government sponsored healthcare programs. It operates through the following segments: Medicaid, Medicare, Commercial, and Other. The Medicaid segment includes the Temporary Assistance for Needy Families program, Medicaid Expansion programs, the Aged, Blind or Disabled program, the Children's Health Insurance Program, Long-Term Services and Supports, Foster Care, Medicare-Medicaid Plans, which cover beneficiaries who are dually eligible for Medicaid and Medicare, and other state-based programs. The Medicare segment consists of Medicare Advantage, Medicare Supplement, Dual Eligible Special Needs Plans, and Medicare Prescription Drug Plans. The Commercial segment is involved in the Health Insurance Marketplace product along with individual, small group, and large group commercial health insurance products. The Other segment refers to pharmacy operations, Envolve Benefit Options' vision and dental services, clinical healthcare, behavioral health, the TRICARE program, and corporate management companies. The company was founded in 1984 and is headquartered in St. Louis, MO. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
FASOLA KENNETH J | Officer | Mar 21 '25 | Proposed Sale | 59.06 | 8,500 | 501,970 | | Mar 21 10:37 AM | Greco Thomas | Director | Dec 18 '24 | Buy | 59.75 | 17,000 | 1,015,750 | 19,309 | Dec 19 05:39 PM | Dallas H James | Director | Dec 16 '24 | Buy | 59.01 | 1,693 | 99,904 | 1,693 | Dec 17 07:34 PM | BLUME JESSICA L. | Director | Dec 16 '24 | Buy | 59.48 | 250 | 14,870 | 250 | Dec 17 07:33 PM | COUGHLIN CHRISTOPHER J | Director | Dec 16 '24 | Buy | 59.44 | 10,000 | 594,400 | 36,358 | Dec 17 07:33 PM |
|
|
|  |
![HLP - Hongli Group Inc - Stock Price Chart]() |
Market Cap | 56.17M | EPS (ttm) | -0.15 |
P/E | - | EPS this Y | - |
Forward P/E | - | EPS next Y | - |
PEG | - | EPS past 5Y | - |
P/S | 3.98 | EPS next 5Y | - |
P/B | 1.05 | EPS Q/Q | -94.64% |
Dividend | - | Sales Q/Q | 0.85% |
Insider Own | 35.39% | Inst Own | 0.00% |
Insider Trans | 0.00% | Inst Trans | -77.42% |
Short Float | 0.08% | Earnings | - |
Analyst Recom | - | Target Price | - |
Avg Volume | 184.64K | 52W Range | 0.72 - 2.12 |
|
|
|
Hongli Group, Inc. is a holding company, which engages in conducting its businesses through its subsidiaries. Its business operation focuses on the design, production, deep processing, and sales of custom-made profile for machinery and equipment. The company was founded on February 9, 2021 and is headquartered in Weifang, China. |
|
 |
![MTVA - MetaVia Inc - Stock Price Chart]() |
Market Cap | 12.69M | EPS (ttm) | -3.36 |
P/E | - | EPS this Y | 68.96% |
Forward P/E | - | EPS next Y | 0.23% |
PEG | - | EPS past 5Y | 67.49% |
P/S | - | EPS next 5Y | 26.17% |
P/B | 1.28 | EPS Q/Q | 72.89% |
Dividend | - | Sales Q/Q | - |
Insider Own | 64.31% | Inst Own | 3.64% |
Insider Trans | 58.76% | Inst Trans | 3.46% |
Short Float | 2.45% | Earnings | May 14/a |
Analyst Recom | 1.00 | Target Price | 13.75 |
Avg Volume | 716.09K | 52W Range | 0.63 - 5.16 |
|
|
|
MetaVia, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing multi-modal disease-modifying therapies. Its pipeline includes ANA001, a proprietary oral niclosamide formulation, Gemcabene, which is assessed as an acute indication for COVID-19, NB-01, a treatment for painful diabetic neuropathy, and NB-02, which has the potential to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases. The company was founded on October 30, 2014 and is headquartered in Cambridge, MA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Woodworth Marshall H | Chief Financial Officer | Jun 04 '25 | Buy | 0.70 | 14,200 | 9,940 | 44,279 | Jun 04 04:01 PM | DONG-A ST CO., LTD | 10% Owner | May 08 '25 | Buy | 0.71 | 4,647,887 | 3,300,000 | 9,995,679 | May 20 04:16 PM |
|
|
 |
![ELV - Elevance Health Inc - Stock Price Chart]() |
Market Cap | 78.59B | EPS (ttm) | 25.63 |
P/E | 13.57 | EPS this Y | 4.36% |
Forward P/E | 8.88 | EPS next Y | 13.62% |
PEG | 1.28 | EPS past 5Y | 6.81% |
P/S | 0.43 | EPS next 5Y | 10.60% |
P/B | 1.85 | EPS Q/Q | 0.19% |
Dividend | 1.95% | Sales Q/Q | 14.83% |
Insider Own | 0.17% | Inst Own | 92.63% |
Insider Trans | -2.17% | Inst Trans | -1.76% |
Short Float | 1.11% | Earnings | Jul 17/b |
Analyst Recom | 1.70 | Target Price | 491.39 |
Avg Volume | 1.85M | 52W Range | 349.61 - 567.26 |
|
|
|
Elevance Health, Inc. operates as a health company, which engages in improving lives and communities, and making healthcare simpler. It operates through the following segments: Health Benefits, CarelonRx, Carelon Services, and Corporate and Other. The Health Benefits segment offers a comprehensive suite of health plans and services to different customers. The CarelonRx segment markets and offers pharmacy services to affiliated health plan customers, as well as to external customers. The Carelon Services segment integrates physical, behavioral, pharmacy, and social services with the aim of delivering whole health affordably by offering a broad array of healthcare related services. The Corporate & Other segment includes businesses that do not individually meet the quantitative threshold for an operating segment. The company was founded in 1944 and is headquartered in Indianapolis, IN. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Kaye Mark | EVP & CFO | Apr 24 '25 | Sale | 424.82 | 4,588 | 1,949,074 | 18,977 | Apr 25 04:17 PM | Kaye Mark | Officer | Apr 24 '25 | Proposed Sale | 424.81 | 4,588 | 1,949,051 | | Apr 24 05:10 PM | Penczek Ronald W | CAO & Controller | Mar 10 '25 | Sale | 415.13 | 443 | 183,903 | 1,847 | Mar 11 04:20 PM | Penczek Ronald W | Officer | Mar 10 '25 | Proposed Sale | 415.13 | 443 | 183,904 | | Mar 10 02:55 PM | Kendrick Charles Morgan JR | EVP & President, Commercial | Mar 05 '25 | Sale | 396.30 | 3,504 | 1,388,635 | 10,116 | Mar 05 05:52 PM |
|
|
|